Novo Nordisk’s practices have raised red flags in Denmark as well as in the US and UK for years, with the more recent ones ...

Novo Nordisk A/S (NYSE:NVO) just hit a technical red flag — a Death Cross. Chart created using Benzinga Pro For those ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Unfortunately, Big Government getting it wrong on food, nutrition, and health did not begin with COVID-19 or even the ...

Novo Nordisk's molecule has the potential to secure ... Getting one more green flag shouldn't be too much of a barrier to continue holding or buying more shares. Alex Carchidi has no position ...

British homebuilder Persimmon said on Wednesday sales rates since the start of the third quarter were well ahead of last year ...

Novo Nordisk’s drug helped reduce knee pain in osteoarthritis patients with obesity. Meanwhile, the Change Healthcare breach ...